Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jovian J Tsang & Harold L Atkins. (2015) The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virotherapy 4, pages 13-23.
Read now
Read now
Jonathan G Pol, Julien Rességuier & Brian D Lichty. (2012) Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment 4, pages 1-21.
Read now
Read now
Articles from other publishers (60)
Heather D. Curtsinger, Xianyi Zeng, Zaira Mather, Mary Ballyk, Tuan Anh Phan, Ben Niu, Jing Pu, Mee Y. Bartee, Jianjun Paul Tian & Eric Bartee. (2023) High Levels of Extracellular Potassium Can Delay Myxoma Virus Replication by Preventing Release of Virions from the Endosomes. Journal of Virology 97:1.
Crossref
Crossref
Mário Sousa-Pimenta, Ângelo Martins & Vera Machado. 2023. Viral Vectors in Cancer Immunotherapy. Viral Vectors in Cancer Immunotherapy
189
219
.
Masmudur M. Rahman, Grant McFadden, Gordon Ruthel, De’Broski.R. Herbert, Bruce D. Freedman, Robert M. Greenberg & Swarna Bais. (2022) Oncolytic Myxoma virus infects and damages the tegument of the human parasitic flatworm Schistosoma mansoni. Experimental Parasitology 239, pages 108263.
Crossref
Crossref
Yaomei Tian, Daoyuan Xie & Li Yang. (2022) Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Victor A. Naumenko, Aleksei A. Stepanenko, Anastasiia V. Lipatova, Daniil A. Vishnevskiy & Vladimir P. Chekhonin. (2022) Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?. Molecular Therapy - Oncolytics 24, pages 663-682.
Crossref
Crossref
Zhilong Yang, Mark Gray & Lake Winter. (2021) Why do poxviruses still matter?. Cell & Bioscience 11:1.
Crossref
Crossref
Fan Guo & Li Xing. (2021) RNA helicase A as co-factor for DNA viruses during replication. Virus Research 291, pages 198206.
Crossref
Crossref
Yvonne Cornejo, Min Li, Thanh H. Dellinger, Rachael Mooney, Masmudur M. Rahman, Grant McFadden, Karen S. Aboody & Mohamed Hammad. (2020)
NSCs are permissive to oncolytic
Myxoma virus
and provide a delivery method for targeted ovarian cancer therapy
. Oncotarget 11:51, pages 4693-4698.
Crossref
Crossref
Joanna Jazowiecka-Rakus, Aleksander Sochanik, Aleksandra Rusin, Agata Hadryś, Wojciech Fidyk, Nancy Villa, Masmudur M. Rahman, Ewa Chmielik, Lina S. Franco & Grant McFadden. (2020) Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma. Molecular Therapy - Oncolytics 18, pages 335-350.
Crossref
Crossref
Nancy.Y. Villa, Masmudur M. Rahman, Joseph. Mamola, Julia D’Isabella, Elizabeth Goras, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Lino Torres, John Christie, Nicole Appel, Anna L. Cox, Jae B. Kim & Grant McFadden. (2020) Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma. Molecular Therapy - Oncolytics 18, pages 171-188.
Crossref
Crossref
Raela B. Ridley, Brianna M. Young, Jieun Lee, Erin Walsh, Chulbul M. Ahmed, Alfred S. Lewin & Cristhian J. Ildefonso. (2019) AAV Mediated Delivery of Myxoma Virus M013 Gene Protects the Retina against Autoimmune Uveitis. Journal of Clinical Medicine 8:12, pages 2082.
Crossref
Crossref
Nancy Y. Villa & Grant McFadden. (2018) Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease. Current Pathobiology Reports 6:4, pages 247-263.
Crossref
Crossref
Marine Ricordel, Johann Foloppe, Christelle Pichon, Annie Findeli, Caroline Tosch, Pascale Cordier, Sandrine Cochin, Eric Quémeneur, Christelle Camus-Bouclainville, Stéphane Bertagnoli & Philippe Erbs. (2018) Oncolytic properties of non-vaccinia poxviruses. Oncotarget 9:89, pages 35891-35906.
Crossref
Crossref
Daniel E. Meyers, Satbir Thakur, Chandini M. Thirukkumaran & Don G. Morris. (2017) Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Blood Cancer Journal 7:12.
Crossref
Crossref
Marine Ricordel, Johann Foloppe, Christelle Pichon, Nathalie Sfrontato, Delphine Antoine, Caroline Tosch, Sandrine Cochin, Pascale Cordier, Eric Quemeneur, Christelle Camus-Bouclainville, Stéphane Bertagnoli & Philippe Erbs. (2017) Cowpox Virus: A New and Armed Oncolytic Poxvirus. Molecular Therapy - Oncolytics 7, pages 1-11.
Crossref
Crossref
Qiu‑Sheng Zhang, Meng Zhang, Xian‑Jian Huang, Xiao‑Jia Liu & Wei‑Ping Li. (2017) Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines. Experimental and Therapeutic Medicine.
Crossref
Crossref
Cameron L. Lilly, Nancy Y. Villa, Ana Lemos de Matos, Haider M. Ali, Jess-Karan S. Dhillon, Tom Hofland, Masmudur M. Rahman, Winnie Chan, Bjarne Bogen, Christopher Cogle & Grant McFadden. (2017) Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Molecular Therapy - Oncolytics 4, pages 31-40.
Crossref
Crossref
Chad Smithson, Nick Tang, Scott Sammons, Mike Frace, Dhwani Batra, Yu Li, Ginny L. Emerson, Darin S. Carroll & Chris Upton. (2016) The genomes of three North American orthopoxviruses. Virus Genes 53:1, pages 21-34.
Crossref
Crossref
Alexandra Pisklakova, Brienne McKenzie, Franz Zemp, Xueqing Lun, Rajappa S. Kenchappa, Arnold B. Etame, Masmudur M. Rahman, Karlyne Reilly, Shari Pilon-Thomas, Grant McFadden, Ebba Kurz & Peter A. Forsyth. (2016) M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro-Oncology 18:8, pages 1088-1098.
Crossref
Crossref
Nancy Villa, Masmudur Rahman, Grant McFadden & Christopher Cogle. (2016) Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses 8:3, pages 85.
Crossref
Crossref
Song Hee Choi, Byoung Kwon Park, Keun-Wook Lee, Jun Chang, Younghee Lee & Hyung-Joo Kwon. (2015) Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Reports 48:10, pages 565-570.
Crossref
Crossref
Wilson Poon, Xuan Zhang, Devesh Bekah, Jose G Teodoro & Jay L Nadeau. (2015)
Targeting B16 tumors
in vivo
with peptide-conjugated gold nanoparticles
. Nanotechnology 26:28, pages 285101.
Crossref
Crossref
Jay Nadeau, Wilson Poon & Xuan Zhang. Mechanisms of cell penetration and cytotoxicity of ultrasmall Au nanoparticles conjugated to doxorubicin and/or targeting peptides. Mechanisms of cell penetration and cytotoxicity of ultrasmall Au nanoparticles conjugated to doxorubicin and/or targeting peptides.
Winnie M. ChanGrant McFadden. (2014) Oncolytic Poxviruses. Annual Review of Virology 1:1, pages 191-214.
Crossref
Crossref
Vaishali Patil & Satya Gupta. 2014. Cancer-Causing Viruses and Their Inhibitors. Cancer-Causing Viruses and Their Inhibitors
437
466
.
Carolina S. Ilkow, Stephanie L. Swift, John C. Bell & Jean-Simon Diallo. (2014) From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer. PLoS Pathogens 10:1, pages e1003836.
Crossref
Crossref
Winnie M. Chan, Masmudur M. Rahman & Grant McFadden. (2013) Oncolytic myxoma virus: The path to clinic. Vaccine 31:39, pages 4252-4258.
Crossref
Crossref
Winnie M. Chan, Eric C. Bartee, Jan S. Moreb, Ken Dower, John H. Connor & Grant McFadden. (2013) Myxoma and Vaccinia Viruses Bind Differentially to Human Leukocytes. Journal of Virology 87:8, pages 4445-4460.
Crossref
Crossref
Craig N. Jenne, Connie H.Y. Wong, Franz J. Zemp, Braedon McDonald, Masmudur M. Rahman, Peter A. Forsyth, Grant McFadden & Paul Kubes. (2013) Neutrophils Recruited to Sites of Infection Protect from Virus Challenge by Releasing Neutrophil Extracellular Traps. Cell Host & Microbe 13:2, pages 169-180.
Crossref
Crossref
Nahlah M Almansour, Elena Pirogova, Peter J Coloe, Irena Cosic & Taghrid S Istivan. (2012) A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro. Journal of Biomedical Science 19:1.
Crossref
Crossref
Eric Bartee, Winnie M. Chan, Jan S. Moreb, Christopher R. Cogle & Grant McFadden. (2012) Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus. Biology of Blood and Marrow Transplantation 18:10, pages 1540-1551.
Crossref
Crossref
Nahlah M Almansour, Elena Pirogova, Peter J Coloe, Irena Cosic & Taghrid S Istivan. (2012) Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. Future Medicinal Chemistry 4:12, pages 1553-1565.
Crossref
Crossref
Rohann J.M. Correa, Monica Komar, Jessica G.K. Tong, Milani Sivapragasam, Masmudur M. Rahman, Grant McFadden, Gabriel E. DiMattia & Trevor G. Shepherd. (2012) Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecologic Oncology 125:2, pages 441-450.
Crossref
Crossref
Sonia Tusell Wennier, Jia Liu, Shoudong Li, Masmudur M. Rahman, Mahmoud Mona & Grant McFadden. (2012) Myxoma Virus Sensitizes Cancer Cells to Gemcitabine and Is an Effective Oncolytic Virotherapeutic in Models of Disseminated Pancreatic Cancer. Molecular Therapy 20:4, pages 759-768.
Crossref
Crossref
Ibtissam Echchgadda, Te-Hung Chang, Ahmed Sabbah, Imad Bakri, Yuji Ikeno, Gene B Hubbard, Bandana Chatterjee & Santanu Bose. (2011) Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer 11:1.
Crossref
Crossref
Danijela Koppers‐Lalic & Rob C. Hoeben. (2011) Non‐human viruses developed as therapeutic agent for use in humans. Reviews in Medical Virology 21:4, pages 227-239.
Crossref
Crossref
Sourav RoyChoudhury, Archana Pan & Debaprasad Mukherjee. (2011) Genus specific evolution of codon usage and nucleotide compositional traits of poxviruses. Virus Genes 42:2, pages 189-199.
Crossref
Crossref
Bart Spiesschaert, Grant McFadden, Katleen Hermans, Hans Nauwynck & Gerlinde R Van de Walle. (2011) The current status and future directions of myxoma virus, a master in immune evasion. Veterinary Research 42:1, pages 76.
Crossref
Crossref
Phonphimon Wongthida, Rosa M Diaz, Feorillo Galivo, Timothy Kottke, Jill Thompson, Alan Melcher & Richard Vile. (2011) VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling. Molecular Therapy 19:1, pages 150-158.
Crossref
Crossref
Peter J. Kerr & Grant McFadden. 2011. The Springer Index of Viruses. The Springer Index of Viruses
1469
1478
.
Jia Liu, Sonia Wennier & Grant McFadden. (2010) The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes and Infection 12:14-15, pages 1144-1152.
Crossref
Crossref
Lila Farrington, Gabriela O'Neill & Ann B. Hill. 2010. The Immune Response to Infection. The Immune Response to Infection
391
401
.
Don B. Gammon, Branawan Gowrishankar, Sophie Duraffour, Graciela Andrei, Chris Upton & David H. Evans. (2010) Vaccinia Virus–Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis. PLoS Pathogens 6:7, pages e1000984.
Crossref
Crossref
M Kim, C T Williamson, J Prudhomme, D G Bebb, K Riabowol, P W K Lee, S P Lees-Miller, Y Mori, M M Rahman, G McFadden & R N Johnston. (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29:27, pages 3990-3996.
Crossref
Crossref
Phonphimon Wongthida, Rosa Maria Diaz, Feorillo Galivo, Timothy Kottke, Jill Thompson, Jose Pulido, Kevin Pavelko, Larry Pease, Alan Melcher & Richard Vile. (2010) Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer. Cancer Research 70:11, pages 4539-4549.
Crossref
Crossref
Nancy Y. Villa, Eric Bartee, Mohamed R. Mohamed, Masmudur M. Rahman, John W. Barrett & Grant McFadden. (2010) Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology 401:2, pages 266-279.
Crossref
Crossref
Laura Evgin, Markus Vähä-Koskela, Julia Rintoul, Theresa Falls, Fabrice Le Boeuf, John W Barrett, John C Bell & Marianne M Stanford. (2010) Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Molecular Therapy 18:5, pages 896-902.
Crossref
Crossref
Sherin E. Smallwood, Masmudur M. Rahman, Dorothy W. Smith & Grant McFadden. (2010) Myxoma Virus: Propagation, Purification, Quantification, and Storage. Current Protocols in Microbiology 17:1, pages 14A.1.1-14A.1.20.
Crossref
Crossref
M Kim, G J Madlambayan, M M Rahman, S E Smallwood, A M Meacham, K Hosaka, E W Scott, C R Cogle & G McFadden. (2009) Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 23:12, pages 2313-2317.
Crossref
Crossref
I Echchgadda, S Kota, I DeLa Cruz, A Sabbah, T Chang, R Harnack, V Mgbemena, B Chatterjee & S Bose. (2009) Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Therapy 16:12, pages 923-935.
Crossref
Crossref
Masmudur M. Rahman, Mohamed R. Mohamed, Manbok Kim, Sherin Smallwood & Grant McFadden. (2009) Co-Regulation of NF-κB and Inflammasome-Mediated Inflammatory Responses by Myxoma Virus Pyrin Domain-Containing Protein M013. PLoS Pathogens 5:10, pages e1000635.
Crossref
Crossref
Timothy P Cripe, Pin-Yi Wang, Paola Marcato, Yonatan Y Mahller & Patrick WK Lee. (2009) Targeting Cancer-initiating Cells With Oncolytic Viruses. Molecular Therapy 17:10, pages 1677-1682.
Crossref
Crossref
Leiliang Zhang, Marianne Stanford, Jia Liu, Catherine Barrett, Lei Jiang, A. Neil Barclay & Grant McFadden. (2009) Inhibition of Macrophage Activation by the Myxoma Virus M141 Protein (vCD200). Journal of Virology 83:18, pages 9602-9607.
Crossref
Crossref
Eric Bartee & Grant McFadden. (2009) Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-β. Cytokine 47:3, pages 199-205.
Crossref
Crossref
Jia Liu, Sonia Wennier, Mary Reinhard, Edward Roy, Amy MacNeill & Grant McFadden. (2009) Myxoma Virus Expressing Interleukin-15 Fails To Cause Lethal Myxomatosis in European Rabbits. Journal of Virology 83:11, pages 5933-5938.
Crossref
Crossref
Eric Bartee, Mohamed R. Mohamed, M. Cecilia Lopez, Henry V. Baker & Grant McFadden. (2009) The Addition of Tumor Necrosis Factor plus Beta Interferon Induces a Novel Synergistic Antiviral State against Poxviruses in Primary Human Fibroblasts. Journal of Virology 83:2, pages 498-511.
Crossref
Crossref
Thi Lien-Anh NguyênHesham AbdelbaryMeztli ArguelloCaroline BreitbachSimon Leveille, Jean-Simon DialloAmber Yasmeen, Tarek A. BismarDavid KirnTheresa FallsValerie E. SnoultenBarbara C. VanderhydenJoel WerierHarold AtkinsMarkus J. V. Vähä-KoskelaDavid F. Stojdl, John C. BellJohn Hiscott. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences 105:39, pages 14981-14986.
Crossref
Crossref
M. Bazan-PeregrinoR.C. CarlisleR. Hernandez-AlcocebaR. IggoK. HomicskoK.D. FisherG. HalldénV. MautnerY. ShenL.W. Seymour. (2008) Comparison of Molecular Strategies for Breast Cancer Virotherapy Using Oncolytic Adenovirus. Human Gene Therapy 19:9, pages 873-886.
Crossref
Crossref
Cheng-Yen Huang, Tsai-Yi Lu, Chi-Horng Bair, Yuan-Shau Chang, Jeng-Kuan Jwo & Wen Chang. (2008) A Novel Cellular Protein, VPEF, Facilitates Vaccinia Virus Penetration into HeLa Cells through Fluid Phase Endocytosis. Journal of Virology 82:16, pages 7988-7999.
Crossref
Crossref
Z. Sheng Guo, Stephen H. Thorne & David L. Bartlett. (2008) Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:2, pages 217-231.
Crossref
Crossref